Lilly to Present New Retatrutide Data at ADA's 86th Scientific Sessions

Eli Lilly has announced it will present a broad slate of new clinical data at the American Diabetes Association's (ADA) 86th Scientific Sessions, including fresh findings on retatrutide, tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity), and the company's newly branded Foundayo indication. The announcement, released via PR Newswire on May 28, 2026, signals that Lilly is building toward what the company describes as "a new era of choice in diabetes and obesity care" — and retatrutide is centre stage in that vision. ### What's on the Agenda The ADA 86th Scientific Sessions, one of the largest and most influential gatherings of diabetes researchers and clinicians worldwide, will feature multiple Lilly-sponsored presentations covering the company's expanding metabolic disease portfolio. While the full abstract list has yet to be published, Lilly has confirmed that retatrutide will feature prominently. The upcoming presentations are expected to include: - **Updated safety and efficacy data** from the ongoing TRIUMPH Phase 3 clinical program, potentially including longer-term follow-up beyond the initial 48-week results announced earlier this year - **Subgroup analyses** examining retatrutide's performance across different patient populations, including those with type 2 diabetes, prediabetes, and various obesity classes - **Combination and sequencing data** exploring how retatrutide fits alongside existing therapies - **Quality-of-life and cardiometabolic outcomes**, an area of growing interest as regulators increasingly emphasize patient-reported outcomes and broader health measures ### Foundayo: A New Name for a New Frontier Lilly's announcement also spotlights Foundayo, the newly named brand for tirzepatide in indications beyond diabetes and obesity — including metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, and heart failure with preserved ejection fraction (HFpEF). The company's decision to create a distinct brand identity for these emerging indications reflects the expanding therapeutic reach of incretin-based therapies. The co-presentation of retatrutide alongside Foundayo and Mounjaro at a major scientific meeting underscores Lilly's comprehensive strategy to dominate the metabolic disease space across multiple mechanisms, patient populations, and disease stages. ### Canadian Context For Canadian healthcare providers and patients, the ADA Scientific Sessions are a critical bellwether for what may soon arrive in Canadian clinical practice. Retatrutide remains under investigation and has not yet been submitted for Health Canada approval, but data presented at meetings like ADA often foreshadow regulatory submissions. Canadian endocrinologists and obesity medicine specialists closely follow ADA presentations, as they frequently inform updates to clinical practice guidelines published by Diabetes Canada and Obesity Canada. If the upcoming data strengthen retatrutide's safety and efficacy profile, it could accelerate the path toward a New Drug Submission in Canada. The 86th Scientific Sessions also come at a pivotal time for diabetes and obesity care in Canada, where over 3 million Canadians live with type 2 diabetes and nearly 11 million are living with obesity or overweight. The potential for a triple-agonist therapy to offer superior outcomes — and potentially cost savings through reduced complication rates — is a topic of intense interest among Canadian health economists and formulary decision-makers at CADTH (Canadian Agency for Drugs and Technologies in Health). ### What This Means for Retatrutide's Timeline Lilly's continued investment in generating and presenting clinical data is a strong signal that the company is progressing toward regulatory filings. The TRIUMPH-1 results, which demonstrated an average weight loss of up to 24.2% at 48 weeks, have already set a high bar. Additional data at ADA could address lingering questions about durability of effect, safety in specific subpopulations, and long-term tolerability. The ADA 86th Scientific Sessions will take place in Orlando, Florida, in June 2026. Canadian researchers are expected to contribute to the proceedings, and the meeting will be streamed virtually for international attendees. ### Sources - **Original Article:** [Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions](https://www.prnewswire.com/news-releases/lilly-to-present-new-data-on-foundayo-mounjaro-and-retatrutide-at-the-american-diabetes-associations-86th-scientific-sessions-building-toward-a-new-era-of-choice-in-diabetes-and-obesity-care-302477543.html) — PR Newswire, May 28, 2026 - Eli Lilly Company Press Release - Diabetes Canada: Diabetes Statistics - Obesity Canada: Obesity in Canada Facts - CADTH: Review Process for Diabetes Therapies